DT in VT
Research type
Research Study
Full title
A Randomised Control Trial of Power versus Temperature-controlled radiofrequency irrigated ablation for the treatment of Ventricular Tachycardia (VT)
IRAS ID
306160
Contact name
Tarv Dhanjal
Contact email
Sponsor organisation
University Hospital Coventry and Warwickshire
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 6 months, 1 days
Research summary
This trial is to compare 2 different types of ablation catheter for the treatment of ventricular tachycardia (VT). VT is a life threatening heart rhythm that comes from the bottom chambers of the heart (the ventricles) and is a leading cause of sudden cardiac death.
Current treatments for VT include catheter ablation (CA), medication and having an internal cardiac defibrillator (ICD) implanted, each treatment has fors and againsts.
The ICD can deliver a lifesaving shock but this doesn’t treat the cause of the VT and can be very painful and upsetting for the patient.
Medications can reduce the amount and rate of VT but can have dangerous side effects.
CA involves small tubes being placed in the heart and small areas of unhealthy heart tissue are burnt (ablated) to stop the VT. This is the only treatment that treats the underlying cause but long-term success is about 50% after 1 year.
We want to improve the success rates of VT ablation. There is a new ablation catheter called Diamond Temp which works differently to the current industry gold standard (Tacticath/Tactiflex Catheter). We think the Diamond Temp catheter will be better than the Tacticath catheter but need to do this trial to prove it.
This trial will be at University Hospital Coventry and Warwickshire involving patients that suffer VT, have an ICD and need an ablation. If a patient wishes to participate they will give consent and be chosen at random to receive ablation with either Diamond temp or Tacticath/Tactiflex. All other treatment will be the same as after a normal ablation procedure. Participants will be followed up at 6 months and 1 year after the procedure as well as being monitored by the ICD clinic. The study will have 54 patients and be completed in 2024.REC name
London - Riverside Research Ethics Committee
REC reference
22/LO/0260
Date of REC Opinion
12 Apr 2022
REC opinion
Favourable Opinion